Replies to post #685050 on NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

NICE won't fund DCVax-L, it will be part of their charity with significant rationing. CAR-T took almost five years after MHRA approval to sell over 100 patient doses a year at greatly reduced prices. No oncology drug makes any material profit in the UK due to price restrictions and rationing coverage.

[dstock07734]

It is certain you have no imagination at all. The reason is simple: you have no fundamental respect for science. I get something for you and the wolf pack which is about some webpages from BPs setup after either the datalock fo the p3 trial or the publication of the JAMA paper.

Better Together Our Aspiration to Cure Cancer
https://takedaoncology.com/news/our-viewpoints/better-together-our-aspiration-to-cure-cancer/
Even Takeda which admitted itself that it had much smaller oncology business is bold enough to dream about curing cancer.

Our oncology business used to be significantly smaller than today, with a portfolio primarily focused on hematologic malignancies, or blood cancers. Now, we also have several solid tumor therapies and have established a robust pipeline focused on leveraging the innate immune system to attack cancer. This progress has positioned us to develop more treatment options for patients who have difficult-to-treat cancers. We’re proud to have grown through thoughtful, strategic partnerships and a deep understanding of the ever-evolving oncology landscape.

The webpage was first recorded by Wayback Machine in September 2022.

https://web.archive.org/web/2022090100

[dstock07734]

Here is something Roche put on its webpage

Either way, we’re on the threshold of a new era for cancer treatment. After years of downplaying the possibility, researchers are even starting to talk about the potential of cure. The immune system has a fantastic memory. Once it has recognised a target, it finds it difficult to forget it – even if its foe tries to hide, moves to a different location, or resurfaces after years of lying hidden. Possibly, all it needs is a little help to get started.

Here is what Daniel Chen, Vice President, Global Head of Cancer Immunotherapy Development at Roche, said about the future.

"In the future, we hope that a patient with cancer will be able to walk into a doctor’s office, have a piece of their tumour biopsied, so that we can understand what’s wrong with their immune response, and then receive a therapy tailored specifically for them."

https://roche.com/stories/roche-in-cancer-immunotherapy

Now check when Roche put such webpage. May 2022!

I love those dates as long as they are after the data-lock of the p3 trial.

https://web.archive.org/web/2022070100

[dstock07734]

In some recent job postings from AstraZeneca, cure for cancer was repeatedly mentioned. AstraZeneca's checking point inhibitor even cannot cure all the hot tumors. What could possibly make the company become so ambitious and optimistic that it can provide cures for cancer in every form?

"AstraZeneca is leading a revolution in cancer care, with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients."

Senior Director, Global Oncology Policy & Advocacy (GI Cancers)
https://careers.astrazeneca.com/job/gaithersburg/senior-director-global-oncology-policy-and-advocacy-gi-cancers/7684/62268377216

Director, Policy & Advocacy - Oncology
https://careers.astrazeneca.com/job/gaithersburg/director-policy-and-advocacy-oncology/7684/62038954976

"Help to advance our pipeline by applying expertise and accelerating our pathway to finding a cure."

Asset Lead, Oncology Outcomes Research (Breast)
https://careers.astrazeneca.com/job/gaithersburg/asset-lead-oncology-outcomes-research-breast/7684/61996298688

Senior Scientist, Oncology Outcomes Research
https://careers.astrazeneca.com/job/gaithersburg/senior-scientist-oncology-outcomes-research/7684/58983866848

Regional Oncology MSL Director, Gynecologic Cancers (WEST)
https://careers.astrazeneca.com/job/wilmington/regional-oncology-msl-director-gynecologic-cancers-west/7684/55871108688

Associate Director, Oncology Outcomes Research (GI)
https://careers.astrazeneca.com/job/gaithersburg/associate-director-oncology-outcomes-research-gi/7684/61033851008

Associate Director, Oncology Outcomes Research
https://careers.astrazeneca.com/job/gaithersburg/associate-director-oncology-outcomes-research/7684/59862306592

"Ambitious and collaborative, we're optimistic in our ability to be resilient and work together towards a cure."

Senior Scientist, Translational Proteomics, Mass Spectrometry
https://careers.astrazeneca.com/job/gaithersburg/senior-scientist-translational-proteomics-mass-spectrometry/7684/61555800448

Senior Scientist, Bioconjugation
https://careers.astrazeneca.com/job/gaithersburg/senior-scientist-bioconjugation/7684/61310462272

[dstock07734]

Our vision: The elimination of cancer
https://www.jnj.com/oncology

Our inspiration: For us, it’s personal
Employees across Johnson & Johnson are working tirelessly to get in front of cancer and create a future where cures are a reality and cancer is eradicated. We listen and learn with compassion to understand the needs of patients, who motivate us to define a new way forward.

https://web.archive.org/web/20210203234437/https://www.jnj.com/oncology

[dstock07734]

https://www.abbvie.com/science/areas-of-focus/oncology.html

People have dedicated their lives to finding a cure.

Building on expertise to tackle the toughest cancers

Our scientific research has led to critical discoveries in the treatment of blood cancer. Now we’re expanding our knowledge to help treat solid tumors, which represent more than 90% of cancers that affect people.

We leverage our deep understanding of human biology and cutting-edge research technologies to find new ways to improve the lives of people with cancer.
Research interests

We focus on creating targeted medicines that either impede the reproduction of cancer cells or enable their death. We achieve this through immuno-oncology approaches, tumor antigen targeting, and taking advantage of specific tumor dependencies. Our research interests include:

Identifying and targeting mechanisms that allow tumor cells to proliferate and survive, including under-explored forms of regulated cell death, such as necroptosis and ferroptosis

Investigating how to re-energize T cells so that they can retain their fitness and continue to destroy tumor cells

Advancing the use of Antibody Drug Conjugates (ADCs) to target and deliver potent toxins and targeted agents directly to cancer cells

Creating new technologies to improve the efficacy of bispecific biologics in treating both solid tumors and blood cancers, enabling the development of therapies with highly targeted potential

Innovating in the field of targeted protein degradation by designing protein degraders that bind to a protein of interest and trigger its proteasomal degradation

Developing CAR-T cell therapies that attack cancers with healthy donor immune cells engineered to target and kill tumor cells while being resistant to host immune system rejection

https://web.archive.org/web/20231002101632/https://www.abbvie.com/science/areas-of-focus/oncology.html

[dstock07734]

https://www.gsk.com/en-gb/behind-the-science-magazine/how-the-next-generation-of-immuno-oncology-could-help-us-get-ahead-of-cancer/

At GSK, our goal is to enable the immune system to target – and potentially cure – all types of cancer.

https://web.archive.org/web/20220819171629/https://www.gsk.com/en-gb/behind-the-science-magazine/how-the-next-generation-of-immuno-oncology-could-help-us-get-ahead-of-cancer/

[dstock07734]

https://www.sanofi.com/en/your-health/medicines/oncology

Until we find cures, we’ll continue to chase miracles of science that transform treatment and care, while addressing the real needs of people living with cancer, such as quality of life.

https://web.archive.org/web/20230827135649/https://www.sanofi.com/en/your-health/medicines/oncology

[Nemesis18]

It is certain you have no imagination at all. The reason is simple: you have no fundamental respect for science.

Science almost demands that imagination is checked by the critical analysis of others, from whatever quarter.

For example, if the submitted Phase 3 results, and the nature of the whole trial construct is being forensically looked at, you should applaud it, in the name of science. ‘?